Golvatinib

Drug Overview

Golvatinib (also known by its developmental code E7050) is an advanced cancer medication designed to disrupt the growth and spread of tumors. In the medical world, it is classified as a Targeted Therapy and is frequently referred to as a “Smart Drug.” Unlike traditional chemotherapy that attacks all fast-growing cells, golvatinib is precision-engineered to find and block specific protein “switches” that cancer cells use to survive.

By targeting multiple pathways at once, golvatinib acts as a multi-threat defense against aggressive cancers. It is particularly used in research for patients whose cancers have become resistant to other treatments, offering a more focused approach to halting disease progression.

• Generic Name: Golvatinib (E7050)
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Small Molecule Tyrosine Kinase Inhibitor (TKI)
• Route of Administration: Oral (Capsule or Tablet)
• FDA Approval Status: Investigational (Currently being studied in clinical trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how this Smart Drug works, imagine a cancer cell is like a high-tech building. To keep the lights on and the doors open, it needs specific “power lines” (signaling pathways). Golvatinib acts like a wire-cutter that snaps two of the most important power lines at the molecular level.

Specifically, golvatinib is a dual inhibitor that targets:

1. The c-Met Pathway: Many cancer cells overproduce a receptor called c-Met. When this receptor is “on,” it tells the cancer cell to multiply, move to other parts of the body (metastasize), and refuse to die. Golvatinib binds to this receptor and switches it “off.”
2. The VEGF Pathway: Tumors need a constant supply of food and oxygen. To get this, they grow their own blood vessels using a signal called VEGFR (Vascular Endothelial Growth Factor Receptor). Golvatinib blocks this signal, effectively “starving” the tumor by preventing new blood vessels from forming.
3. Molecular Precision: By blocking both c-Met and VEGFR simultaneously, golvatinib prevents the cancer cell from finding a “detour” around the treatment. This dual action makes it harder for the tumor to develop resistance.

FDA Approved Clinical Indications

As an investigational drug, golvatinib is currently available primarily through clinical trials. Researchers are testing its power against several difficult-to-treat cancers.

Oncological Uses (Investigational)

• Hepatocellular Carcinoma (Liver Cancer): For patients whose cancer has progressed after standard treatments.
• Glioblastoma (Brain Cancer): Being studied for its ability to cross the blood-brain barrier.
• Solid Tumors: Investigated for use in various advanced cancers that show c-Met mutations.
• Combination Therapy: Often studied alongside other drugs like sorafenib to see if it increases their effectiveness.

Non-Oncological Uses

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Because golvatinib is in the testing phase, the exact doses are determined by clinical trial protocols to ensure patient safety.

Dose Adjustments:

• Hepatic Insufficiency (Liver Issues): Since the liver processes this drug, doctors may lower the dose for patients with liver damage.
• Renal Insufficiency (Kidney Issues): Patients with kidney issues are monitored closely, though specific dose changes are still being determined in ongoing trials.

Clinical Efficacy and Research Results

Recent clinical research (2020–2025) has focused on how golvatinib helps patients whose cancer has stopped responding to other “Smart Drugs.”

• Tumor Shrinkage: In Phase I/II trials, golvatinib has shown the ability to achieve “Stable Disease” or “Partial Response” in a significant percentage of patients with advanced liver cancer.
• Disease Progression: Numerical data from research suggests that golvatinib can delay the time it takes for a tumor to grow back (Progression-Free Survival) by several months in specific patient groups.
• Overcoming Resistance: Studies have highlighted that golvatinib can be effective even when the cancer has developed a “bypass” to older inhibitors, showing its strength as a next-generation targeted therapy.

Safety Profile and Side Effects

Like all targeted therapies, golvatinib can cause side effects because the proteins it blocks are also found in some healthy parts of the body.

Black Box Warning:

None. (Investigational drugs do not yet have formal Black Box Warnings).

Common Side Effects (>10%)

• Fatigue: Feeling unusually tired or weak.
• Diarrhea: Loose or frequent stools.
• Nausea: General stomach upset.
• Hypertension: High blood pressure (caused by blocking blood vessel signals).
• Decreased Appetite: A reduced desire to eat.

Serious Adverse Events

• Proteinuria: Too much protein in the urine, which can signal kidney stress.
• Hepatotoxicity: Signs of liver inflammation or stress.
• Hand-Foot Syndrome: Redness, swelling, or pain on the palms of the hands and soles of the feet.

Management Strategies

• Blood Pressure Monitoring: Patients are often asked to check their blood pressure at home daily.
• Liver Tests: Frequent blood tests are required to ensure the liver is handling the medicine safely.

Research Areas

Golvatinib is a major focus in Combination Immunotherapy research. Scientists are exploring if blocking c-Met and VEGFR can “unmask” a tumor, making it easier for the body’s natural immune system to find and destroy it. There is also early research into using golvatinib alongside Stem Cell markers to see if the drug can target the “root” cells that cause cancer to return after chemotherapy.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Genetic Profiling: To see if the tumor has the c-Met protein that golvatinib targets.
• Liver Function Tests (LFTs): To check baseline liver health.
• Baseline Blood Pressure: To have a starting point for heart health monitoring.

Precautions During Treatment

• Monitor Vitals: Keep a log of your daily blood pressure and any new headaches.
• Skin Care: Use thick, fragrance-free moisturizers on your hands and feet to prevent peeling.

“Do’s and Don’ts” List

• Do take the medication exactly as prescribed by your trial doctor.
• Do stay hydrated to help your kidneys process the medication.
• Don’t take new herbal supplements (like St. John’s Wort) without asking, as they can stop the drug from working.
• Don’t ignore a sudden, severe headache or vision changes, as these can be signs of high blood pressure.

Legal Disclaimer

Standard Medical Information Disclaimer: This guide is for informational purposes only and does not constitute medical advice. Golvatinib is an investigational drug and is only available through approved clinical trials. Always consult with a licensed oncologist or healthcare professional to discuss treatment options, risks, and benefits specific to your medical history. This information is based on clinical data available as of early 2026.